课题基金 / 基金详情

MODULATION OF THERAPEUTIC RESPONSE

MODULATION OF THERAPEUTIC RESPONSE
治疗反应的调节
批准号:
6123647
负责人:
J B MITCHELL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

J B MITCHELL的其他基金

相似基金

相关文献

中文摘要
翻译
“为了改善癌症治疗, 相当多的注意力已经放在修改 辐射损伤该项目的主要目标是继续定义 并了解独特的肿瘤生理学,解剖学, 细胞和分子过程,最终定义了 肿瘤的性质使得特定剂量的电离辐射, 使用时,会更有效。达到这一目的的一种手段是 研究电离辐射与各种 化疗药物,以评估肿瘤是否可以使更多的 敏感我们证明了对一个不同的人的治疗 紫杉醇诱导肿瘤细胞G2/M期阻滞 周期(细胞周期的放射敏感期),导致 显著的放射增敏作用。因此,翻译这个 将临床前信息转化为临床试验, 紫杉醇治疗头颈癌目前 放射肿瘤学分支正在进行。其他 化疗剂(喜树碱衍生物,米托蒽醌, 和埃博噻酮等)正在研究, 确定其作为辐射增敏剂的用途。公 确定缺氧是辐射的主要决定因素 灵敏度因此,我们正在使用几种小鼠肿瘤模型, 研究肿瘤缺氧。我们的方法是利用目前的侵入性 并将这些信息扩展到非侵入性方法 正在开发中,这样患者的肿瘤治疗 可以在个体的基础上优化简档。为此,我们 使用体外/体内存活技术,基于荧光的氧 探针,硝基咪唑固定,然后免疫组织化学, F-18硝基咪唑PET扫描,血氧水平 测定(BOLD)NMR,电子顺磁共振, 和Overhauser NMR。我们得到的信息会告诉我们 如何以非侵入性方式评估肿瘤中的氧状态, 达到最佳治疗效果。同样,理解和定义 肿瘤血管和DNA表达应该提供洞察力, 了解新血管生成如何影响肿瘤氧含量, 因此,对辐射的反应,以及提供 关于那些基因的信息,这些基因是在响应 氧化应激几种血管抑素和内皮抑素的表达 已经构建了用于直接肿瘤内注射的载体, 全身脂质体递送。此外,体外/体内肿瘤 包含具有开关的向量的模型, 目前正在制备内皮抑制素和血管抑制素, 可以在以下背景下评估血管分布的影响: 对辐射的反应性,以及在非侵入性的情况下, 功能成像肿瘤内的基因表达作为以下因素的函数 氧状态、再灌注、电离辐射暴露和一般 正在研究氧化应激以确定这些分子 在肿瘤细胞反应性中重要的事件, 单独或联合电离辐射损伤的存活率 药物制剂。目的是扩大我们对 肿瘤微环境、生理学和分子生物学, 将这些知识与非侵入性的研究方法联系起来, 这样我们就能设计出有效的治疗方案 联合或同时使用放射治疗和药物治疗 剂. "
英文摘要
"In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The major goal of this project continues to define and understand those aspects of unique tumor physiology, anatomy, cellular, and molecular processes that ultimately define the very nature of a tumor such that a particular dose of ionizing radiation, when used, will be more effective. One means to that end is to investigate the interaction of ionizing radiation with a variety of chemotherapy agents to assess if tumors can be made more sensitive. We demonstrated that treatment of a diverse human tumor cell lines with paclitaxel induced a block in G2/M of the cell cycle (radiosensitive phases of the cell cycle) which resulted in significant radiosensitization. As a consequence, translation of this pre-clinical information into a clinical trail combining radiation and paclitaxel in the treatment of head/neck cancer is currently underway in the Radiation Oncology Branch. Other chemotherapeutic agents (camptothecin derivatives, mitoxanthone, and epothialones, among others) are being investigated to determine their use as radiation sensitizing agents. It is well established that hypoxia is a major determinant of radiation sensitivity. Therefore, we are using several murine tumor models to study tumor hypoxia. Our approach is to use current invasive techniques and extend that information to non-invasive methods that are under development, such that patient tumor treatment profiles may optimized on an individual basis. To that end we are using in vitro/in vivo survival techniques, fluorescent based oxygen probes, nitroimidazole fixation followed by immunohistochemistry, F-18 nitroimidazole PET scanning, blood oxygen level determination (BOLD) NMR, electron paramagnetic resonance, and Overhauser NMR. The information we acquired will teach us how to assess oxygen status in a tumor in a non-invasive manner to effect optimum treatment. Likewise, understanding and defining tumor vasculature and DNA expression should provide insight to understanding how neoangiogenesis impacts on tumor oxygen and consequently responsiveness to radiation, as well as provide information regarding those genes that are expressed in response to oxidative stress. Several angiostatin and endostatin expression vectors have been constructed for direct intra-tumor injection or systemic liposome delivery. Moreover, in vitro/in vivo tumor models containing vectors with switches for expression of endostatin and angiostatin are being made presently, such that the impact of vascularity can be assessed in the context of responsiveness to radiation and also in the context of non-invasive functional imaging. Gene expression within a tumor as a function of oxygen status, reperfusion, ionizing radiation exposure and general oxidative stress is being investigated to determine those molecular events that are important in the tumor cell responsiveness and survival to insult by ionizing radiation alone or in combination with pharmacologic agents. The aim is to extend our knowledge of tumor micro-environment, physiology, and molecular biology and to correlate such knowledge with non-invasive methods of studying tumors so that we design efficient and effective treatment protocols using radiation in combination or tandem with pharmacologic agents."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NITROXIDES AS PROTECTORS AGAINST OXIDATIVE STRESS
RADIOSENSITIZATION OF AERATED AND HYPOXIC MAMMALIAN CELLS
  • 批准号:
    4692099
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J B MITCHELL
  • 依托单位:
RADIOSENSITIZATION AND CHEMOSENSITIZATION OF AERATED AND HYPOXIC MAMMALIAN CELLS
  • 批准号:
    3838050
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J B MITCHELL
  • 依托单位:
RESPONSE OF MAMMALIAN CELLS TO HALOGENATED PYRIMIDINES
  • 批准号:
    3874412
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J B MITCHELL
  • 依托单位:
海外基金